CPP
BXRX

Crow Point Partners’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Crow Point Partners’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$173K Buy
+18
New +$154K 0.27% 67

Other funds holding BXRX

CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ECM
Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
NRC
North Run Capital Boston, Massachusetts $43.5M AUM 38.24% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
NRCM
Northern Right Capital Management Darien, Connecticut $281M AUM 56.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Crow Point Partners's BXRX Position: Q4 2019 in Review

Crow Point Partners opened a new position in Baudax Bio, Inc. Common Stock (BXRX) in Q4 2019: 18 shares worth $173K. The stake represents 0.27% of the portfolio and ranks #67 among its holdings.

53 funds tracked by Wall St. Rank hold BXRX as of Q4 2019.

  • Crow Point Partners held 18 shares of Baudax Bio, Inc. Common Stock worth $173K as of Q4 2019.
  • Baudax Bio, Inc. Common Stock was a new Crow Point Partners position in Q4 2019.
  • Baudax Bio, Inc. Common Stock made up 0.27% of Crow Point Partners's portfolio in Q4 2019, its #67 holding.
  • 53 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q4 2019.

Based on Crow Point Partners's 13F filing for Q4 2019, filed 14 Feb 2020.